Medicine guide
Uplizna 100 mg/10ml
As listed in the register: Uplizna 100 mg/10ml, Konzentrat zur Herstellung einer Infusionslösung
100 mg/10ml ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Inebilizumabum
- Made by
- Amgen Switzerland AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Behandlung von erwachsenen Patienten mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD), die Anti-Aquaporin-4-Immunglobulin G(AQP4-IgG)-seropositiv sind
From the official label · 2026-09-30 · Swissmedic
Details
| Made by | Amgen Switzerland AG |
|---|---|
| Active substance | Inebilizumabum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 100 mg/10ml |
| Classification | L04AA47 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Uplizna 100 mg/10ml, Konzentrat zur Herstellung einer Infusionslösung |
| Packs | 3 Durchstechflasche(n) |
| Zulassungsnummer | 69322 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.